Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8875999 | 1.00 | HTR6 (0.53) | HTR6CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL6180265 | 0.81 | HTR6 (0.53) | HTR6CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL1067208 | 0.81 | CHRM2 (0.64) | HTR6CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL1067210 | 0.81 | CHRM2 (0.64) | HTR6CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL722273 | 0.80 | HTR6 (0.54) | HTR6CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL1697440 | 0.80 | HTR6 (0.54) | HTR6CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL773348 | 0.80 | HTR6 (0.54) | HTR6CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL774709 | 0.80 | HTR6 (0.54) | HTR6CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL5647758 | 0.79 | HTR6 (0.66) | HTR6CHRM2HTR1AADRA2ACHRM1 | |
| Bromide SCHEMBL505857 | 0.79 | HTR6 (0.65) | HTR6CHRM2HTR1AADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1199969-C | New process for the preparation of the anti-migraine drug | PFIZER LTD (US) | 2005-05-04 | — | — | CN | disclosed |
| CN-1487932-A | New process for the preparation of the anti-migraine drug | — | 2004-04-07 | — | — | CN | disclosed |
| US-20030166704-A1 | New process | PFIZER INC. | 2003-09-04 | — | — | US | disclosed |
| US-5607951-A | SEROTONIN AGONIST FOR NERVOUS SYSTEM DISORDERS, ANALGESICS AND PSYCHOTHERAPEUTICS | PFIZER INC (US) | 1997-03-04 | — | — | US | disclosed |
| US-5578612-A | Indole derivatives | PFIZER INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-5559129-A | SEROTONIN (5HT1) ANTAGONIST FOR TREATMENT OF DEPRESSION, ANXIETY, EATING DISORDERS, OBESITY, DRUG ABUSE, HEADACHES, AND PAIN | PFIZER INC (US) | 1996-09-24 | — | — | US | disclosed |
| US-5559246-A | PROCESS OF DEHYDROHALOGENATION FOR CYCLIZATION TO PRODUCE PSYCHOTHERAPEUTIC AGENTS AND ANTISEROTONIN ANTAGONIST | PFIZER INC. (US) | 1996-09-24 | — | — | US | disclosed |
| US-5545644-A | SEROTONIN AGONISTS; HYPOTENSIVE AND ANXIOLYTIC AGENTS; ANALGESICS; ANTIDEPRESSANTS; EATING DISORDERS; DRUG ABUSE; HEADACHES; VASCULAR DISORDERS | PFIZER INC. (US) | 1996-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166704-A1 | New process | TFPI, HTR4, HTR5A | HTR6 20/4885CHRM2 803/4885HTR1A 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.